In Samara, develop a test to identify the risks of complications in the treatment of cancer

Scientists of Samara State Medical University (SamSMU) are developing test systems that will help to identify the risk of heart damage in patients with cancer in advance. The study will allow you to select antitumor therapy, taking into account the individual characteristics of the body.

According to the head of the Department of Hematology and Chemotherapy No. 2 Clinic SamSMU Olesya Danilova, clinically pronounced cardiotoxicity occurs in 20-30% of patients undergoing antitumor treatment. Some drugs can cause complications from the cardiovascular system. In some cases, this leads to the suspension of chemotherapy or a decrease in the dosage of drugs.

Now doctors use diagnostic methods that can detect already occurring heart damage. The new development should help to identify a predisposition to such complications before starting treatment.

A patient's blood sample will be sufficient. Specialists will be able to determine the genetic features associated with the risk of cardiotoxicity, and based on the results to choose the safest treatment regimen. If necessary, the patient will also be prescribed drugs to protect the heart.

So far, researchers have identified genetic variants that will form the basis of test systems. On the subject of the project, 12 results of intellectual activity were obtained, including patents and certificates of registration of programs and databases. 15 scientific articles were also published.

The development is carried out by the team of the Department of Hematology and Chemotherapy No. 2 Clinic SamSMU. In 2027, scientists plan to create a laboratory sample of the test system.

For this project, Olesya Danilova became the winner of the VI annual award named after Academician A. I. Savitsky in the nomination “Oncohematologist of the Year”.

-

Follow the latest news of Samara and the Samara region in our social networks!We are in Telegram | in MAX | in Zen